NL-OMON36241已完成不适用
Bosentan improves clinical Outcome of adults with congenital heart disease or mitral valve lesions who undergo CArdiac surgery - BOCA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adults with CHD or with mitral valve lesions who undergo cardiac surgery.
排除标准
- •* Current treatment with bosentan
- •* Systemic arterial pressure < 85 mmHg
- •* Incapable of giving informed consent
- •* Ejection fraction below 30 %
- •* Hypersensitivity to bosentan or any of its help substances
- •* Moderate to severe liver disease: Child-Pugh class B or C
- •* Raised plasma transaminases level > three times limiting value.
- •* Simultaneous use of cyclosporine A
- •* Percutaneous Transluminal Angioplasty procedures
研究者
相似试验
Unknown
不适用
Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac SurgeryCongenital Heart DiseaseNCT01184404Berto J Bouma100
进行中（未招募）
不适用
The role of Bosentan in fontan patients: improvement of aerobic capacity - bosentan in fontan patientsTo study whether bosentan (endothelin receptor inhibitor) improves aerobic capacity (VO2max) and exercise performance in adult patients with a Fontan operation.MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-004533-21-NLICI50
进行中（未招募）
不适用
Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACProgressive pulmonary sarcoidosisMedDRA version: 9.1Level: PTClassification code 10037430Term: Pulmonary sarcoidosisEUCTR2007-005117-18-ATMedical University of Vienna, Department of Clinical Pharmacology
尚未招募
不适用
The role of Bosentan in fontan patients: improvement of aerobic capacity.aerobic capacity (peak V’O2)quality of life prevalence of arrhythmiasprevalence of protein losing enteropathyNL-OMON24216none40
招募中
2 期
The effect of Bosentan in the treatment of pulmonary hypertension in patients with COVID-19Condition 1: COVID-19. Condition 2: COVID-19.COVID-19, virus not identifiedCOVID-19, virus identifiedU07.2U07.1IRCT20210710051831N1Qazvin University of Medical Sciences60